ASH Annual Meeting

Adding blinatumomab to chemotherapy led to a significant improvement in disease-free survival in pediatric patients with standard-risk pediatric B-ALL.

An all-oral regimen combining revumenib with decitabine/cedazuridine (ASTX727) and venetoclax reached high remission rates in patients with acute myeloid leukemia with certain genetic alterations.

Among patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, MRD-negativity rates and progression-free survival were improved with daratumumab plus VRd versus VRd alone.

Updated results from the phase 2 AUGMENT-101 trial showed that revumenib continued to provide clinically meaningful responses in patients with relapsed or refractory acute leukemia with a KMT2Ar translocation.

Fatima Tuz Zahra, MD, discusses the methods and design of a retrospective analysis of 65 patients with acute myeloid leukemia treated with oral azacitidine maintenance after achieving complete remission.

Palak Dave discusses the diagnostic challenges between myelodysplastic syndrome and pre-MDS conditions.

Akriti Jain, MD, discusses what she is most looking forward to seeing presented at the upcoming 2024 American Society of Hematology Annual Meeting and Exposition.

Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.

Dipti Patel-Donnelly, MD, highlights challenges for physicians and patients when managing treatment of hematologic malignancies in the community setting.

Susan Bal, MD, discusses novel targets for relapsed/refractory multiple myeloma at the 2023 Annual Meeting.

Anita Kumar, MD, discusses findings from the phase 2 study of zanubrutinib, obinutuzumab, and venetoclax in TP53-mutant mantle cell lymphoma presented at ASH 2023.

Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.

The majority of patients with relapsed chronic lymphocytic leukemia treated with zanubrutinib or ibrutinib in the phase 3 ALPINE study did not acquire a BTK or PLCG2 mutation.

Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.

DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials.

Stephen Schuster, MD, discusses findings from follow-up of the phase 2 ELARA study presented at the 2023 ASH Annual Meeting.

Investigators report that response-adapted trials utilizing novel combination regimens appear to be safe and feasible in a population of patients with newly diagnosed diffuse large B-cell lymphoma.

Updated safety and subgroup analyses appear consistent with previously reported results from the phase 2 ZUMA-12 study of axicabtagene ciloleucel for patients with high-risk large B-cell lymphoma.

Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.

The treatment combination of isatuximab with carfilzomib, lenalidomide, and dexamethasone resulted in a 100% objective response rate among patients with newly diagnosed multiple myeloma.

David J. Andorsky, MD, discusses findings from a retrospective study of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma from ASH 2023.

The novel BTK degrader BGB-16673 was well tolerated; produced meaningful and rapid clinical responses; and demonstrated on-target effects in patients with relapsed/refractory B-cell malignancies.

The ongoing LuminICE phase 2 study demonstrated that AFM13 in combination with AB-101 may hold promise for the treatment of patients with relapsed or refractory CD30-positive lymphomas.

A comparison of asciminib and bosutinib demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase chronic myeloid leukemia.

A new targeted therapy showed promising response rates in pediatric and adult patients with relapsed/refractory KMT2A rearranged acute leukemia.

Anitocabtagene autoleucel showcased early efficacy with acceptable toxicity in patients with relapsed and/or refractory multiple myeloma—even in those with high-risk features.

Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival and complete response rate.

Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant and D-VRd consolidation and daratumumab/lenalidomide maintenance significantly prolonged progression-free survival.

Treatment with the novel agent NX-2127 was safe and efficacious in patients with B-cell malignancies, according to recent phase I data.

Study findings support the use of a financial navigation program, in hopes to aid patients with multiple myeloma affected by financial toxicity.